The increasing popularity of Amazon’s annual Prime Day, Cyber Monday, and other online shopping-themed occasions is one of many indicators more Americans are relying on mobile devices and computers, not malls, to shop.
It’s no secret the so-called “Amazon effect,” a... Read more »
The deal VMware unveiled this week to buy cybersecurity firm Carbon Black triggered a heaping share of skepticism.
“I’m having a hard time with the Carbon Black acquisition,” said Jeffries analyst John Stephen DiFucci on a conference call with VMware executives.... Read more »
An experimental GlaxoSmithKline treatment for multiple myeloma has achieved the main goal of a key study, and the drug maker plans to file for regulatory approval by the end of this year.
GlaxoSmithKline (NYSE: GSK) said Friday that treatment with... Read more »
Biotech news tends to slow down in August but the past seven days have been busy for regulatory decisions. Three drugs and two devices won FDA nods.
Not all companies were as fortunate. Several biotechs reported failed clinical trials or unfavorable... Read more »
A slower news week for Boston technology news, but not without its fireworks. Among them: Researchers are not taking the news well that MIT Media Lab director Joi Ito had extensive financial arrangements with Jeffrey Epstein, the convict and alleged child... Read more »
About 15 percent of adults in the US, around 37 million people, are estimated to have chronic kidney disease, according to the Centers for Disease Control. They have very few therapeutic options and often progress to kidney failure, which is treatable... Read more »
VMware is shelling out big bucks for two companies to fill out its technology stack: developer platform Pivotal Software for $2.7 billion and cybersecurity firm Carbon Black for $2.1 billion.
“These acquisitions address two critical technology priorities of all businesses today—building... Read more »
[Corrected, 8/23/19, see below] Retrophin, the drug developer founded by jailed former biotech executive Martin Shkreli, has failed its first big test.
The San Diego-based company’s experimental drug fosmetpantotenate failed a Phase 3 trial, FORT, in patients with a... Read more »
John Halamka thinks the digital health industry is still “emerging.” But it has come a long way and is starting to deliver after years of hype.
Halamka, a Boston-based physician and healthcare technology expert, says that’s thanks to several coalescing factors:... Read more »
Splunk, an IT operations management and information security company, announced today it has clinched a deal to buy cloud software application monitoring company SignalFx for $1.05 billion.
San Francisco-based Splunk (NASDAQ: SPLK) says the acquisition will enable it to... Read more »
Ford subsidiary Autonomic today announced a step forward in its drive to expand the online mobility hub it built to manage digital interactions among cars, drivers, fleets, service providers, and auto manufacturers—including Ford’s rivals.
Palo Alto, CA-based Autonomic signed up Ayro... Read more »
If you care about life science and the people and issues driving the future, you will want an Xcelerate pass to this year’s Biotech Week Boston. Hurry, our Super Saver sale ends Friday!
The Xcelerate program package provides access to four... Read more »
Nearly four years ago, the FDA approved a therapy that uses a virus to infect tumor cells and break them down—the first such viral therapy for treating cancer. Oncorus CEO Ted Ashburn says there’s room to improve on these oncolytic viruses... Read more »